Загрузка...
A phase‐1, open‐label, single‐dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment
The pharmacokinetics (PK) and safety of single‐dose buparlisib (30 mg) were assessed in subjects with mild to severe hepatic impairment (n = 6 each) relative to healthy controls (n = 13). Blood samples were collected until 336 hours postdose and evaluated by liquid chromatography tandem mass spectro...
Сохранить в:
| Опубликовано в: : | J Clin Pharmacol |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5049450/ https://ncbi.nlm.nih.gov/pubmed/26183800 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.590 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|